Compare · ANIP vs ELOX
ANIP vs ELOX
Side-by-side comparison of ANI Pharmaceuticals Inc. (ANIP) and Eloxx Pharmaceuticals Inc. (ELOX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. ANIP focuses on Biotechnology: Pharmaceutical Preparations, while ELOX focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- ANIP is the larger of the two at $1.74B, about 22.3x ELOX ($77.9M).
- ANIP has been more active in the news (7 items in the past 4 weeks vs 3 for ELOX).
- ANIP has more recent analyst coverage (12 ratings vs 5 for ELOX).
- Company
- ANI Pharmaceuticals Inc.
- Eloxx Pharmaceuticals Inc.
- Price
- -
- -
- Market cap
- $1.74B
- $77.9M
- 1M return
- -8.31%
- -
- 1Y return
- -19.29%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 7
- 3
- Recent ratings
- 12
- 5
ANI Pharmaceuticals Inc.
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract manufacturing for other pharmaceutical companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was founded in 2001 and is headquartered in Baudette, Minnesota.
Eloxx Pharmaceuticals Inc.
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
Latest ANIP
- ANI Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors
- SR. VP, GENERAL COUNSEL & SEC. Cook Meredith sold $37,740 worth of shares (500 units at $75.48) as part of a pre-agreed trading plan, decreasing direct ownership by 0.67% to 74,424 units (SEC Form 4)
- SVP, GENERICS Gutwerg Ori sold $243,474 worth of shares (3,162 units at $77.00), decreasing direct ownership by 4% to 75,534 units (SEC Form 4)
- SEC Form 10-Q filed by ANI Pharmaceuticals Inc.
- ANI Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results
- SVP & CFO Carey Stephen P. sold $231,876 worth of shares (2,850 units at $81.36) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 174,693 units (SEC Form 4)
- ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ET
- SR. VP, GENERAL COUNSEL & SEC. Cook Meredith covered exercise/tax liability with 2,466 shares, decreasing direct ownership by 3% to 74,924 units (SEC Form 4)
Latest ELOX
- Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
- SEC Form 8-K filed by Eloxx Pharmaceuticals Inc.
- SEC Form 10-Q filed by Eloxx Pharmaceuticals Inc.
- Guggenheim initiated coverage on Eloxx Pharmaceuticals with a new price target
- Large owner Domicilium Real Estate Fund Iii Lp acquired 600,000 shares (SEC Form 4)
- New insider Domicilium Real Estate Fund Iii Lp claimed ownership of 14,285 shares (SEC Form 3)
- SEC Form 4 filed by Director Kjellson Nina S
- SEC Form 4 filed by Director Webster Stephen W
- SEC Form 4 filed by Director Walts Alan Edmund
- SEC Form 4 filed by Director Rubin Steven D